EGFR Amplification clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
“Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”
open to eligible people ages 18 years and up
The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.
at UC Davis UCLA UCSD
Our lead scientists for EGFR Amplification research studies include Andrew Birkeland, MD Deborah Wong, MD Assuntina Sacco, MD.
Last updated: